Compare Check Point Software Technologies Ltd (CHKP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Novo Nordisk A/S — how do they compare? Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 15.8× Check Point Software Technologies Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| CHKP | NVO | |
|---|---|---|
Market Cap | $13.18B | $207.85B |
Sector | Technology | Health |
52-Week High | $206.91 | $63.98 |
52-Week Low | $112.47 | $35.29 |
Enterprise Value | $12.88B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Check Point Software Technologies (CHKP) trades at $128.21, down 2.23% on the day, reflecting recent bearish pressure. The stock shows strong profitability with a net margin of 37.93% and has beaten earnings estimates for three consecutive quarters. Technical indicators signal a bearish trend, with the price near support at $128. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a P/E of 13.24, but growth challenges and margin pressures pose risks. Analyst consensus leans neutral with a $146.92 price target, suggesting cautious optimism for recovery driven by AI security demand, though competitive and execution risks remain.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
